Comparing two doses of entecavir for hepatitis B cirrhosis
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have cirrhosis caused by hepatitis B.
- You have detectable hepatitis B virus in your blood.
- You have no signs of liver cancer or hepatitis C coinfection.
- You are not currently on antiviral medication.
- You are not pregnant and have no allergy to entecavir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.